Certara, Inc. $CERT is ArrowMark Colorado Holdings LLC’s 5th Largest Position

ArrowMark Colorado Holdings LLC reduced its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 6.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,378,543 shares of the company’s stock after selling 510,886 shares during the quarter. Certara makes up 1.7% of ArrowMark Colorado Holdings LLC’s investment portfolio, making the stock its 5th biggest holding. ArrowMark Colorado Holdings LLC owned about 4.63% of Certara worth $90,166,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CERT. First Horizon Corp acquired a new stake in Certara during the 3rd quarter worth $30,000. Versant Capital Management Inc lifted its position in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after acquiring an additional 1,153 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in Certara in the second quarter valued at $59,000. Finally, Global Retirement Partners LLC grew its holdings in shares of Certara by 45.0% during the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock worth $69,000 after purchasing an additional 1,749 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Up 1.4%

NASDAQ CERT opened at $6.65 on Friday. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1.06 billion, a P/E ratio of -665.00 and a beta of 1.50. Certara, Inc. has a 52-week low of $6.04 and a 52-week high of $15.38. The firm has a 50-day moving average price of $7.98 and a 200 day moving average price of $9.61.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. During the same period in the prior year, the firm posted $0.15 EPS. Certara’s revenue for the quarter was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Barclays reiterated an “equal weight” rating and set a $8.00 target price on shares of Certara in a research report on Friday, March 6th. TD Cowen reissued a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 price target on the stock. in a research note on Friday, February 27th. Leerink Partners reaffirmed an “outperform” rating and set a $10.00 price target on shares of Certara in a research report on Thursday, February 26th. Finally, KeyCorp reduced their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $11.10.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.